Rad AI Named to CNBC Disruptor 50 List For Pioneering Generative AI in Healthcare
Recognition comes amid rapid growth, with Rad AI recently securing $68 million in Series C Funding and ranking 19th on the Deloitte Fast 500.
SAN FRANCISCO, June 10, 2025 /PRNewswire/ -- Rad AI, the leader in generative AI for healthcare, today announced it was named to the 2025 CNBC Disruptor 50 list. The annual list recognizes the most innovative, fast-growing private companies that are disrupting established industries using breakthrough technologies. This recognition further solidifies Rad AI's position as the leader in pioneering AI-driven solutions that improve radiologist efficiency, reduce burnout, and enhance patient care.
The CNBC Disruptor 50 recognition follows a remarkable period of company growth that includes several recent milestones:
Closed $68M Series C, including strategic investments from some of the nation's most respected health systems.
Ranked #19 on the 2024 Deloitte Fast 500.
"Being named to the CNBC Disruptor 50 list is an incredible honor for Rad AI," said Doktor Gurson, CEO and co-founder of Rad AI. "Since our founding in 2018, we've believed that AI should empower—not replace—radiologists. Our mission has always been to deliver AI-driven solutions that save time, reduce burnout, and elevate patient care. This recognition from CNBC not only highlights our impact in transforming healthcare through AI, but also reinforces our ongoing commitment to creating meaningful, lasting change in the lives of physicians and patients alike."
Today, Rad AI is the leading provider of generative AI solutions for radiology workflow optimization and patient follow-up management, with its solutions trusted by over 50% of U.S. health systems and 9 of the 10 largest radiology practices in the country.
Rad AI was the first company to deploy large language model (LLM)-based generative AI into radiology workflows with its groundbreaking Rad AI Impressions solution. As the company continues to lead innovation in healthcare AI, it is rapidly expanding its network of strategic partnerships and accelerating efforts to bring its transformative technology to more providers across the globe. Rad AI is making significant investments in partner support, advancing product innovation, and scaling its AI-powered platform to additional health systems and radiology practices.
To learn more about Rad AI's solutions, visit www.radai.com.
About Rad AI Rad AI is the leader in generative AI solutions for radiology, transforming the way radiologists work and improving patient care. The company's flagship product, Rad AI Reporting, streamlines radiology reporting with AI-driven technology and empowers radiologists to achieve greater efficiency, accuracy, and satisfaction. Rad AI Impressions, the company's pioneering product, established Rad AI as an innovator in generative AI for radiology; as the first generative AI application to achieve widespread adoption in radiology, it is now trusted by thousands of U.S. radiologists. Rad AI Continuity, the most comprehensive solution of its kind, provides AI-driven patient follow-up.
Rad AI is the fastest-growing radiologist-led AI company and has been recognized as one of the most promising healthcare AI companies by CB Insights (Digital Health 50, AI 100) and AuntMinnie (Best New Radiology Software). Rad AI was named the 19th fastest-growing company in North America on the Deloitte Fast 500. Most recently, in April 2025, Rad AI was named the 4th fastest-growing private company on the Inc. Regionals Pacific list.
Learn more about Rad AI at www.radai.com or on LinkedIn at www.linkedin.com/company/radai/
PR Contact: Wei Ting Hsieh, Rad AI, weiting.hsieh@radai.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rad-ai-named-to-cnbc-disruptor-50-list-for-pioneering-generative-ai-in-healthcare-302477571.html
SOURCE Rad AI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Trump Likely to Extend Tariff Pause as Negotiations Take Shape, Treasury Secretary Says
U.S. Treasury Secretary Scott Bessent said it's 'highly likely' that President Donald Trump will extend his July 9 reciprocal tariff deadline to continue negotiations with trade partners. Following two days of discussions in London with Chinese officials which resulted in a patched-up trade truce, Bessent testified in front of the House Ways and Means Committee on Wednesday, telling members of Congress that the administration is 'working toward deals' with '18 important trading partners' or blocs, in the case of the European Union. More from Sourcing Journal China-to-US Freight Rates 'No Longer Surging'-Is it All Downhill from Here? DHL Makes $570 Million Splash in the Middle East Trump Touts Higher Duty Rate for Chinese Imports Under New Trade Deal Those deals may take more time to complete, Bessent hinted, saying that countries that are 'negotiating in good faith' could see extensions on the tariff deadline. 'If someone is not negotiating, then we will not,' he added. Just one month remains until the double-digit 'Liberation Day' duties that the president announced on April 2 will go into effect. With negotiations between the Washington and Beijing reaching an apparent consensus, Commerce Secretary Howard Lutnick said trade-focused members of Trump's team, including himself, Bessent, and U.S. Trade Representative (USTR) Ambassador Jamieson Greer, will now be focused on other deals. 'Our teams are moving them forward… we're going to be focused starting today,' he said during an interview on CNBC, noting that the U.S. is in 'good shape with a lot of countries' and could see 'deal after deal' as soon as next week. 'We've got lots of them in the hopper. We just want to make sure they're the best deal we possibly can make. We don't want to rush,' he said. Lutnick confirmed that dealmaking with the E.U. has been tense. 'Europe was more than thorny,' he told the news outlet, saying, 'they just weren't really engaging.' In late May, Trump threatened the E.U. with sweeping 50-percent tariffs—significantly higher than the 20 percent announced in April—saying leaders had been 'difficult to deal with' and that the negotiations were 'going nowhere.' The president accused the trade bloc of maintaining high trade barriers and value-added taxes (VAT) on American goods, among other complaints. At the time, he said the heightened duty rate would help address the trade deficit between Europe and the U.S., which totaled $235 billion in 2024, according to USTR data. Lutnick echoed Trump's sentiments on Wednesday, telling CNBC that the sheer breadth of the negotiations, which will result in trade rules that apply to 27 European countries, makes it 'tough' to come to a resolution. Within the scope of the administration's trade deal agenda, 'Europe will be probably the very, very end,' he said. Lutnick also commented on recent legal setbacks that the president's tariff regime has suffered, referencing a ruling by a Court of International Trade that the duties, applied under the International Emergency Economic Powers Act (IEEPA), were illegal. A federal appeals court granted a stay on that decision as it reviews the cases brought against the president, and the tariffs are allowed to move forward—for now. The Commerce Secretary said 'ultimately, it's not going to matter' what the courts rule because the president has a number of executive authorities and avenues to pursue to execute his tariff plan.
Yahoo
38 minutes ago
- Yahoo
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
44 minutes ago
- CNBC
The importance of Iran's energy complex. Here's a breakdown
CNBC's Pippa Stevens joins 'The Exchange' to discuss Iran's energy complex and the country's impact on the oil trade.
